
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0"/>
  <title>ABBV 20211231 Analysis</title>
  <link rel="stylesheet" href="styles.css" />
</head>

<body>
  <header>
    <h1>ABBV 20211231 Analysis</h1>
  </header>

  <nav>
    <ul>
      <li><a href="#business">üöÄ Business Development</a></li>
      <li><a href="#risk">‚öñÔ∏è Risk and Opportunities</a></li>
      <li><a href="#financials">üìä Financials</a></li>
      <li><a href="#recommend">üìà Recommendation</a></li>
    </ul>
  </nav>

  <main>
    <!-- url -->
    <section id="business" class="module">
      <h2>üîé Source Data</h2>
      <p>
        <!-- Your text goes here. -->
        <a href="https://www.sec.gov/Archives/edgar/data/1551152/000155115222000007/abbv-20211231.htm">source filing at SEC</a>
      </p>
    </section>
  
    <!-- Business Development (text only) -->
    <section id="business" class="module">
      <h2>üöÄ Business Development</h2>
      <p>
        <!-- Your text goes here. -->
        - Skyrizi (IL-23 inhibitor) expanded indications to include active psoriatic arthritis in the U.S. and EU, with approvals in Japan for plaque psoriasis, generalized pustular psoriasis, and psoriatic arthritis.  <br>- Rinvoq (JAK inhibitor) gained U.S. approval for moderate-to-severe atopic dermatitis in adults/adolescents and expanded into EU/Japan for rheumatoid arthritis and psoriatic arthritis.  <br>- Immunology portfolio growth driven by Humira (37% of 2021 revenue), with new pediatric ulcerative colitis and uveitis approvals in North America/Europe and Japan indications for intestinal Beh√ßet‚Äôs disease.  <br>- Aesthetics segment expanded globally via Botox Cosmetic/Therapeutic and Juvederm Collection, leveraging Allergan integration for market penetration and international infrastructure.  <br>- Neuroscience portfolio strengthened by Ubrelvy (migraine) and Qulipta (CGRP inhibitor) launches, alongside Vraylar‚Äôs expanded use in bipolar depression and adjunctive MDD treatment.  <br>- Hematologic oncology leadership maintained through Imbruvica‚Äôs market position and Venclexta‚Äôs indication expansions in AML/CLL, supported by clinical trial advancements.  <br>- Allergan acquisition synergies targeted $2.5B annual cost savings by 2022, optimizing manufacturing, supply chain, and commercial operations through integration efforts.  <br>- R&D investments focused on 90+ ongoing clinical programs, including regulatory submissions for next-gen aesthetics products and neuroscience pipeline assets like ABBV-951 for Parkinson‚Äôs.  <br>- COVID-19 operational adaptations ensured supply chain continuity and clinical trial safety, though lower new patient starts impacted certain therapies temporarily.  <br>- Dividend increased 8.5% to $1.41/share (Feb 2022), reflecting strong cash flow and commitment to shareholder returns alongside debt reduction strategies.
      </p>
    </section>

    <!-- Risk and Opportunities (text only) -->
    <section id="risk" class="module">
      <h2>‚öñÔ∏è Risk and Opportunities</h2>
      <p>
        <!-- Your text goes here. -->
        Risks:<br>- COVID-19 pandemic impacts operations through reduced new patient starts, supply chain disruptions, and uncertain long-term demand dynamics<br>- Humira's U.S. patent expiration in 2023 creates imminent biosimilar competition risk for 37% of total revenue<br>- High debt burden ($64B long-term debt) limits financial flexibility and increases interest payment obligations<br>- Significant goodwill ($32B) and intangible assets ($76B) face impairment risks from market/clinical trial changes<br>- Cybersecurity vulnerabilities in IT systems could disrupt operations and compromise sensitive data<br><br>Opportunities:<br>- Immunology portfolio expansion with Skyrizi/Rinvoq growth (+50% Y/Y) across 15+ autoimmune indications<br>- Hematologic oncology leadership through Venclexta label expansions and Imbruvica market dominance<br>- Aesthetics growth via global Botox Cosmetic/Juvederm demand and premium product innovation<br>- Neuroscience pipeline including migraine therapies Ubrelvy/Qulipta and psychiatric drug Vraylar<br>- 70+ clinical programs across immunology/oncology with 2022 regulatory submissions for 8 new indications
      </p>
    </section>

    <!-- Financials (with 4 image cards + 5 horizontal sections of text) -->
    <section id="financials" class="module">
      <h2>üìä Financials</h2>

      <!-- Four cards with images (responsive layout) -->
      <div class="card-container">
        <div class="card">
          <img src="ABBV_20211231_1.jpg" alt="Financial Chart 1" />
        </div>
        <div class="card">
          <img src="ABBV_20211231_2.jpg" alt="Financial Chart 2" />
        </div>
        <div class="card">
          <img src="ABBV_20211231_3.jpg" alt="Financial Chart 3" />
        </div>
        <div class="card">
          <img src="ABBV_20211231_4.jpg" alt="Financial Chart 4" />
        </div>
      </div>

      <!-- 5 horizontal sections (each a text paragraph) -->
      <section class="horizontal-section" id="key-items">
        <h3>Key Items</h3>
        <p>
          <!-- Your text goes here. -->
          - Total operating costs and expenses decreased from 75.16% (2020) to 68.09% (2021) of revenue (-7.07%), driving operating earnings up from 24.80% to 31.91% (+7.11%).  <br>- Other expense, net declined from 12.25% to 4.45% of revenue (-7.80%), contributing to earnings before income tax increasing from 7.42% to 23.10% (+15.68%).  <br>- Income tax expense shifted from -2.67% (2020) to +2.56% (2021) (+5.23%), with net earnings rising from 10.09% to 20.55% (+10.46%) and attributable net earnings mirroring this growth.  <br>- Total revenue grew 23.0% YoY, gross profit increased 27.3%, income from operations surged 57.8%, and net income spiked 149.6% from 2020 to 2021.  <br>- Long-term debt and finance lease obligations decreased by 7.70% as a percentage of total liabilities and equity, reducing leverage.  <br>- Total shareholders' equity expanded 17.83% YoY, strengthening the company‚Äôs equity position.
        </p>
      </section>

      <section class="horizontal-section" id="profitability-analysis">
        <h3>Profitability Analysis</h3>
        <p>
          <!-- Your text goes here. -->
          - Net profit margin increased from 10.07% (2020) to 20.5% (2021) due to 23% revenue growth ($56.2B) and controlled operating expense growth below revenue rates.  <br>- Operating profit margin rose from 24.8% to 31.9%, driven by $2.5B annual cost savings from Allergan acquisition synergies and improved cost management.  <br>- ROA doubled from 3.07% to 7.87% through higher net earnings (+157%) despite slight asset reduction, reflecting improved asset utilization efficiency.  <br>- ROE surged from 35.2% to 74.7% as net earnings growth outpaced a 13% decrease in total equity, demonstrating enhanced equity efficiency.  <br>- Gross profit margin improved from 66.4% to 68.9% via better production cost control, with cost of products sold increasing slower than revenue growth.  <br>- Strategic portfolio growth (including full Allergan integration) and pipeline investments supported revenue diversification while maintaining expense discipline.  <br>- Shareholder returns through dividends and buybacks optimized capital structure, contributing to profitability ratio improvements.  <br>- Operational efficiency gains were amplified by acquisition-related restructuring savings and SG&A expense management relative to sales growth.
        </p>
      </section>

      <section class="horizontal-section" id="liquidity-analysis">
        <h3>Liquidity Analysis</h3>
        <p>
          <!-- Your text goes here. -->
          - Current ratio declined from 0.843 (2020) to 0.794 (2021) due to current liabilities increasing $1.628B (accounts payable/other liabilities), outpacing asset growth  <br>- Quick ratio decreased from 0.728 to 0.705 as accounts receivable rose $1.321B from higher sales, but remained less liquid than cash equivalents  <br>- Cash ratio dipped slightly (0.296 to 0.280) as cash/short-term investments growth (+$1.1B) lagged behind liability expansion  <br>- Inventory decreased marginally, improving asset efficiency but slightly reducing current assets available for liquidity coverage  <br>- Current liabilities surged 18.6% year-over-year compared to 12.3% current asset growth, driven by operational financing needs  <br>- Strong cash from operations ($23.1B in 2021 vs $21.7B in 2020) was offset by accelerated liability accumulation  <br>- Accounts receivable growth reflected increased product demand but extended cash conversion cycles  <br>- Profitability improved significantly with net earnings rising 129.5% ($4.879B to $11.202B), enhancing future liquidity potential  <br>- Liquidity position remains solvent despite ratio declines, supported by robust earnings and disciplined inventory management  <br>- Monitoring required for short-term obligation coverage given liability growth trajectory relative to liquid assets
        </p>
      </section>

      <section class="horizontal-section" id="solvency-analysis">
        <h3>Solvency Analysis</h3>
        <p>
          <!-- Your text goes here. -->
          - Debt-to-Equity Ratio decreased from 10.49 (2020) to 8.5 (2021) due to long-term debt reduction ($77.55B to $64.19B) and increased equity ($18.25B to $23.52B), reflecting improved capital structure and reduced leverage.  <br>- Interest Coverage Ratio rose from 4.98x to 7.52x, driven by operating earnings growth ($11.36B to $17.92B) from strong revenue performance, Allergan acquisition benefits, and operational efficiency.  <br>- Debt-to-Asset Ratio declined from 91.2% to 89.5% as debt reduction outpaced a slight total asset decrease ($150.57B to $146.53B), indicating better debt management relative to assets.  <br>- Strong cash flow from operations ($22.8B in 2021) supported debt servicing and growth investments, aligning with strategic priorities to enhance financial stability and shareholder returns.  <br>- Equity growth and profitability improvements underscore AbbVie's focus on optimizing balance sheet strength and long-term solvency, reducing financial risk.
        </p>
      </section>

      <section class="horizontal-section" id="efficiency-analysis">
        <h3>Efficiency Analysis</h3>
        <p>
          <!-- Your text goes here. -->
          - DSO improved from 69 days (2020) to 63 days (2021) due to net revenue growth (+22%) outpacing accounts receivable growth (+13%), reflecting stronger collections efficiency.  <br>- DIO decreased by 11 days (77 days in 2020 to 66 days in 2021) as inventory levels dropped 5.5% despite a 13% COGS increase, indicating optimized inventory turnover.  <br>- DPO increased slightly from 377 days (2020) to 379 days (2021) as accounts payable grew 12.6% alongside COGS, maintaining consistent supplier terms and negotiating power.  <br>- CCC improved by 19 days to -250 days (2021) from -231 days (2020), driven by DSO/DIO reductions and stable DPO, accelerating cash conversion relative to payment obligations.  <br>- Operational improvements included Allergan acquisition synergies, cost management, and demand-aligned inventory strategies, enhancing working capital efficiency.  <br>- Negative CCC demonstrates ability to generate cash from operations faster than settling payables, supported by $56.2B net revenue (2021) and $17.4B COGS scalability.
        </p>
      </section>
    </section>

    <!-- Recommendation (text only) -->
    <section id="recommend" class="module">
      <h2>üìà Recommendation:  ‚úÖ  BUY</h2>
      <p>
        <!-- Your text goes here. -->
        Based on the analysis of AbbVie's financial statements, the company has shown consistent revenue growth, improved operating and net earnings, and strong EPS growth. The company's ability to manage debt effectively, improve profitability ratios, and enhance its equity position all contribute to a positive outlook. While potential risks such as regulatory changes and competition exist, the overall positive trends suggest that AbbVie is well-positioned for continued growth, leading to an expected increase in next year's earnings per share.
      </p>
    </section>
  </main>

  <footer>
    <p>¬© 2025 SnapStock Report</p>
  </footer>
</body>
</html>


